tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksMarket MoversTipRanks 50 IndexDividend StocksAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

ARCT Stock Latest News

Arcturus Therapeutics: Promising mRNA Developments and High Upside Potential Justify Buy Rating
RatingsArcturus Therapeutics: Promising mRNA Developments and High Upside Potential Justify Buy Rating
19d ago
ARCT
3 Best Stocks to Buy Now, 7/7/2025, According to Top Analysts
PremiumMarket News
3 Best Stocks to Buy Now, 7/7/2025, According to Top Analysts
27d ago
FC
ARCT
Arcturus Therapeutics price target raised to $35 from $32 at Scotiabank
PremiumThe Fly
Arcturus Therapeutics price target raised to $35 from $32 at Scotiabank
1M ago
ARCT
Positive Outlook for ARCT-810: Safety and Efficacy Indicators Justify Buy Rating
PremiumRatings
Positive Outlook for ARCT-810: Safety and Efficacy Indicators Justify Buy Rating
1M ago
ARCT
Positive Outlook for Arcturus Therapeutics: Promising mRNA Technology and Competitive Edge in Urea-Cycle Disorders
PremiumRatings
Positive Outlook for Arcturus Therapeutics: Promising mRNA Technology and Competitive Edge in Urea-Cycle Disorders
1M ago
ARCT
Positive Outlook for Arcturus Therapeutics Amid Promising Developments in ARCT-810 and ARCT-032 Programs
PremiumRatingsPositive Outlook for Arcturus Therapeutics Amid Promising Developments in ARCT-810 and ARCT-032 Programs
1M ago
ARCT
Citi adds ‘upside 90-day catalyst watch’ on Arcturus Therapeutics
Premium
The Fly
Citi adds ‘upside 90-day catalyst watch’ on Arcturus Therapeutics
1M ago
ARCT
Arcturus Therapeutics: Buy Rating Affirmed Amid Promising OTC Developments and Upcoming CF Catalyst
Premium
Ratings
Arcturus Therapeutics: Buy Rating Affirmed Amid Promising OTC Developments and Upcoming CF Catalyst
1M ago
ARCT
Promising Potential of Arcturus Therapeutics’ mRNA Therapies Drives Buy Rating
PremiumRatings
Promising Potential of Arcturus Therapeutics’ mRNA Therapies Drives Buy Rating
1M ago
ARCT
Arcturus Therapeutics Announces Positive Phase 2 Results
PremiumCompany Announcements
Arcturus Therapeutics Announces Positive Phase 2 Results
1M ago
8K
ARCT
Arcturus announces ‘positive’ interim Phase 2 multiple dose data for ARCT-810
PremiumThe Fly
Arcturus announces ‘positive’ interim Phase 2 multiple dose data for ARCT-810
1M ago
ARCT
Positive Outlook on Arcturus Therapeutics Driven by Promising mRNA Advancements and Strategic Developments
PremiumRatings
Positive Outlook on Arcturus Therapeutics Driven by Promising mRNA Advancements and Strategic Developments
2M ago
ARCT
Arcturus Therapeutics Approves Key Proposals at Annual Meeting
PremiumCompany AnnouncementsArcturus Therapeutics Approves Key Proposals at Annual Meeting
2M ago
8K
ARCT
Arcturus Therapeutics: Strategic Shift to Rare Disease Therapeutics and Strong Financial Position Drive Buy Rating
Premium
Ratings
Arcturus Therapeutics: Strategic Shift to Rare Disease Therapeutics and Strong Financial Position Drive Buy Rating
2M ago
ARCT
Arcturus Therapeutics initiated with an Outperform at Scotiabank
Premium
The Fly
Arcturus Therapeutics initiated with an Outperform at Scotiabank
2M ago
ARCT
Arcturus Therapeutics: Earnings Call Highlights Progress and Challenges
PremiumCompany Announcements
Arcturus Therapeutics: Earnings Call Highlights Progress and Challenges
3M ago
ARCT
Arcturus Therapeutics price target lowered to $45 from $50 at Wells Fargo
PremiumThe Fly
Arcturus Therapeutics price target lowered to $45 from $50 at Wells Fargo
3M ago
ARCT
Arcturus Therapeutics: Strategic Focus and Promising CF Program Drive Buy Rating
PremiumRatings
Arcturus Therapeutics: Strategic Focus and Promising CF Program Drive Buy Rating
3M ago
ARCT
Promising Developments and Strategic Financial Management Drive Buy Rating for Arcturus Therapeutics
PremiumRatings
Promising Developments and Strategic Financial Management Drive Buy Rating for Arcturus Therapeutics
3M ago
ARCT
Arcturus Therapeutics price target lowered to $66 from $68 at Canaccord
PremiumThe FlyArcturus Therapeutics price target lowered to $66 from $68 at Canaccord
3M ago
ARCT
Citi opens ’90-day Upside Catalyst Watch’ on Arcturus Therapeutics
Premium
The Fly
Citi opens ’90-day Upside Catalyst Watch’ on Arcturus Therapeutics
3M ago
ARCT
Strategic Shift to mRNA Therapeutics Positions Arcturus for Significant Upside
Premium
Ratings
Strategic Shift to mRNA Therapeutics Positions Arcturus for Significant Upside
3M ago
ARCT

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >